Alpha Teknova Inc
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample m… Read more
Alpha Teknova Inc (TKNO) - Net Assets
Latest net assets as of September 2025: $72.65 Million USD
Based on the latest financial reports, Alpha Teknova Inc (TKNO) has net assets worth $72.65 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($107.62 Million) and total liabilities ($34.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $72.65 Million |
| % of Total Assets | 67.5% |
| Annual Growth Rate | 44.85% |
| 5-Year Change | 57.23% |
| 10-Year Change | N/A |
| Growth Volatility | 132.37 |
Alpha Teknova Inc - Net Assets Trend (2019–2024)
This chart illustrates how Alpha Teknova Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alpha Teknova Inc (2019–2024)
The table below shows the annual net assets of Alpha Teknova Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $82.39 Million | -8.49% |
| 2023-12-31 | $90.04 Million | -9.86% |
| 2022-12-31 | $99.89 Million | -30.25% |
| 2021-12-31 | $143.20 Million | +173.26% |
| 2020-12-31 | $52.41 Million | +305.93% |
| 2019-12-31 | $12.91 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alpha Teknova Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11722600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $200.92 Million | 243.86% |
| Total Equity | $82.39 Million | 100.00% |
Alpha Teknova Inc Competitors by Market Cap
The table below lists competitors of Alpha Teknova Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
It's Skin Co Ltd
KO:226320
|
$28.73 Million |
|
1911 Gold Corp
OTCQB:AUMBF
|
$28.73 Million |
|
Grupo Ezentis S.A
MC:EZE
|
$28.73 Million |
|
SundayToz Corp
KQ:123420
|
$28.73 Million |
|
WithTech Inc.
KQ:348350
|
$28.72 Million |
|
Azimut Exploration Inc
OTCQX:AZMTF
|
$28.72 Million |
|
S Connect Co. LTD
KQ:096630
|
$28.71 Million |
|
SIKRI GROUP ASA NK-02
F:57U0
|
$28.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alpha Teknova Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 90,036,000 to 82,394,000, a change of -7,642,000 (-8.5%).
- Net loss of 26,745,000 reduced equity.
- Share repurchases of 135,000 reduced equity.
- New share issuances of 15,104,000 increased equity.
- Other factors increased equity by 4,134,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.75 Million | -32.46% |
| Share Repurchases | $135.00K | -0.16% |
| Share Issuances | $15.10 Million | +18.33% |
| Other Changes | $4.13 Million | +5.02% |
| Total Change | $- | -8.49% |
Book Value vs Market Value Analysis
This analysis compares Alpha Teknova Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.78x to 1.57x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $3.55 | $2.77 | x |
| 2020-12-31 | $13.18 | $2.77 | x |
| 2021-12-31 | $5.11 | $2.77 | x |
| 2022-12-31 | $3.56 | $2.77 | x |
| 2023-12-31 | $2.83 | $2.77 | x |
| 2024-12-31 | $1.76 | $2.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alpha Teknova Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -70.86%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.44x
- Recent ROE (-32.46%) is below the historical average (-21.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -10.11% | -6.49% | 0.34x | 4.53x | $-2.60 Million |
| 2020 | 6.81% | 11.41% | 0.50x | 1.20x | $-1.67 Million |
| 2021 | -6.85% | -26.57% | 0.22x | 1.16x | $-24.12 Million |
| 2022 | -47.52% | -114.60% | 0.27x | 1.52x | $-57.46 Million |
| 2023 | -40.85% | -100.26% | 0.29x | 1.43x | $-45.78 Million |
| 2024 | -32.46% | -70.86% | 0.32x | 1.44x | $-34.98 Million |
Industry Comparison
This section compares Alpha Teknova Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $439,452,927
- Average return on equity (ROE) among peers: -31.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alpha Teknova Inc (TKNO) | $72.65 Million | -10.11% | 0.48x | $28.72 Million |
| Ascend Wellness Holdings Inc (AAWH) | $71.80 Million | -118.37% | 11.54x | $48.90 Million |
| AB Science S.A (ABSCF) | $-21.01 Million | 0.00% | 0.00x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-294.68K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $195.20 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $29.91 Million | 0.00% | 0.07x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.72 Million | -18.78% | 0.11x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $20.08 Million | -10.91% | 0.33x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.85 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.25 Billion | 5.19% | 0.72x | $85.61 Million |